revascularizacion incompleta en cirugia no cardiaca

Best Revascularization Strategy in Patients with Left Ventricular Deterioration

Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy.  According to this recent analysis of the SCAAR registry published in the European Heart Journal, long term followup seems to justify taking a higher risk initially, higher risk being myocardial revascularization surgery (CABG). The study looked at<a href="https://solaci.org/en/2021/08/11/best-revascularization-strategy-in-patients-with-left-ventricular-deterioration/" title="Read more" >...</a>

SOLACI Research | Invitation to Participate in the Latin American SOLACI Peripheral Registry

After much effort, SOLACI Research is pleased to formally invite the entire community to participate in the Latin American SOLACI Peripheral Registry, our second research initiative.  The SOLACI Peripheral Registry is a multicenter, prospective registry that aims to collect data on the reality of lower limb angioplasty in Latin America, in order to unify criteria,<a href="https://solaci.org/en/2021/07/16/solaci-research-invitation-to-participate-in-the-latin-american-solaci-peripheral-registry/" title="Read more" >...</a>

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Efficacy of the Novavax Vaccine Against COVID-19: Nanoparticle Technology to the Test

In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7). The Novavax vaccine is a recombinant nanoparticle containing full-length spike glycoprotein. It had already been shown to be safe and<a href="https://solaci.org/en/2021/07/16/efficacy-of-the-novavax-vaccine-against-covid-19-nanoparticle-technology-to-the-test/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600 patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting<a href="https://solaci.org/en/2021/07/13/novel-des-technology-promises-to-become-the-next-des-generation/" title="Read more" >...</a>

The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use?

Here is the third Fellow’s Corner clinical case to keep discussing and learning alongside the entire community of hemodynamics fellows in Latin America. In this instance, we will present a case of True Bifurcation Lesion: Which Strategy Should We Use? Content 1- Case Presentation 2- Case Resolution 3- Expert Commentary Authors: Dr. Carlos Fava (ARG)<a href="https://solaci.org/en/2021/07/05/the-fellows-corner-3rd-clinical-case-true-bifurcation-lesion-which-strategy-should-we-use/" title="Read more" >...</a>

European Consensus on Antithrombotic Management in TAVR

All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR). While thrombotic and hemorrhagic complications have diminished over time—as both the technique and the devices have been perfected—, they still remain as common adverse events in TAVR.  Recommendations in the 2017 European Guidelines were<a href="https://solaci.org/en/2021/06/28/european-consensus-on-antithrombotic-management-in-tavr/" title="Read more" >...</a>

Miocardiopatía hipertrófica: análisis de una serie histórica

Differences in American and European Atrial Fibrillation Guidelines

The recent publication of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) guidelines provided an important update on multiple aspects of the management of atrial fibrillation (AF). However, these guidelines differ in terms of management and recommendation levels. As it might be expected, most differences arose in intermediate cases—both guidelines<a href="https://solaci.org/en/2021/06/07/differences-in-american-and-european-atrial-fibrillation-guidelines/" title="Read more" >...</a>

Nuevo dispositivo para medición del FFR permite cruzar la lesión con nuestra guía preferida

FLOWER-MI: FFR vs. Angiography for Complete Revascularization in Infarction

Functional assessment with fractional flow reserve (FFR) was not better than conventional angiography to guide complete revascularization in patients with multivessel lesions in a setting of ST-segment elevation myocardial infarction and successful primary angioplasty. These results were published in the New England Journal of Medicine (NEJM) and presented during the American College of Cardiology (ACC)<a href="https://solaci.org/en/2021/06/07/flower-mi-ffr-vs-angiography-for-complete-revascularization-in-infarction/" title="Read more" >...</a>

EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging

According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months as Xience in angioplasty guided by intravascular imaging. This research was presented at the virtual EuroPCR 2021 Congress. Previous studies (BIOSTEMI and BIOFLOW V) showed that Orsiro was superior to Xience in reducing target-lesion revascularization. However, the reason behind this<a href="https://solaci.org/en/2021/05/29/europcr-2021-castle-orsiro-vs-xience-guided-by-intravascular-imaging/" title="Read more" >...</a>

EuroPCR 2021 | Un nuevo meta-análisis desafía al ISCHEMIA

EuroPCR 2021 | A New Meta-Analysis Challenges the ISCHEMIA Trial

This paper suggests that patients with stable coronary artery disease who undergo elective coronary revascularization find a long-term benefit in terms of cardiac death compared with patients who receive medical treatment alone. These findings, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal, challenge the results from the ISCHEMIA trial. Researchers state<a href="https://solaci.org/en/2021/05/26/europcr-2021-a-new-meta-analysis-challenges-the-ischemia-trial/" title="Read more" >...</a>